$1.20
2.56% today
Nasdaq, Feb 28, 05:19 pm CET
ISIN
US63909J1088
Symbol
NAUT
Sector
Industry

Nautilus Biotechnology Stock price

$1.17
-0.67 36.41% 1M
-1.47 55.68% 6M
-0.51 30.36% YTD
-1.77 60.20% 1Y
-2.83 70.75% 3Y
-9.27 88.79% 5Y
-9.27 88.79% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.26 18.18%
ISIN
US63909J1088
Symbol
NAUT
Sector
Industry

Key metrics

Market capitalization $146.91m
Enterprise Value $37.87m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.66
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-81.50m
Free Cash Flow (TTM) Free Cash Flow $-61.02m
Cash position $140.61m
EPS (TTM) EPS $-0.56
P/E forward negative
Short interest 0.65%
Show more

Is Nautilus Biotechnology a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Nautilus Biotechnology Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Nautilus Biotechnology forecast:

2x Buy
50%
1x Hold
25%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a Nautilus Biotechnology forecast:

Buy
50%
Hold
25%
Sell
25%

Financial data from Nautilus Biotechnology

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 6.39 6.39
27% 27%
-
-6.39 -6.39
27% 27%
-
- Selling and Administrative Expenses 21 21
5% 5%
-
- Research and Development Expense 48 48
12% 12%
-
-75 -75
11% 11%
-
- Depreciation and Amortization 6.39 6.39
27% 27%
-
EBIT (Operating Income) EBIT -81 -81
12% 12%
-
Net Profit -70 -70
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nautilus Biotechnology directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nautilus Biotechnology Stock News

Neutral
Seeking Alpha
about 5 hours ago
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brenn...
Neutral
GlobeNewsWire
4 months ago
Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging
Neutral
GlobeNewsWire
4 months ago
SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference.
More Nautilus Biotechnology News

Company Profile

Nautilus Biotechnology, Inc. develops proteomics platform for analyzing and quantifying the human proteome. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Sujal Patel
Employees 167
Founded 2016
Website www.nautilus.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today